Definium Therapeutics said on Wednesday its LSD-based experimental pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial’s main goal and sending the drug developer’s shares up more than 20% premarket.
President Donald Trump signed an executive order directing federal agencies to speed up access to research and treatments based on psychedelic drugs for serious mental health conditions. In April, U.S. The trial is Definium’s second late-stage success for DT120, following a positive readout in a depression study in June.
The benefit emerged as early as two days after dosing and lasted throughout the 12-week study.
RBC Capital Markets analyst Brian Abrahams said the data exceeded Wall Street’s expectations and the efficacy seen with other therapies for the disease. No new drug has been approved for the condition in nearly two decades, according to Brian Barnett, a Cleveland Clinic psychiatrist who worked on the study.
